Background This study assessed the clinical efficacy of nirmatrelvir plus ritonavir (NMV-r) in
treating patients with COVID-19 who have preexisting cardiovascular diseases (CVDs) …

Background There is limited evidence of association of nirmatrelvir-ritonavir (NMV-r) and
incidence of postacute sequelae of SARS-CoV-2 infection (PASC) in patients with pre …

Although a novel oral antiviral agent can improve short‐term COVID‐19 outcomes, its effects
on the long‐term outcomes, namely the risk of major adverse cardiovascular events …

Objective To assess the effectiveness of nirmatrelvir-ritonavir in the treatment of outpatients
with mild to moderate COVID-19 who are at higher risk of developing severe illness, through …

Nirmatrelvir-ritonavir (NMVr) is used to treat symptomatic, nonhospitalized patients with
coronavirus disease-2019 (COVID-19) who are at high risk of progression to severe …

At present, there are some differences in the research results of nirmatrelvir–ritonavir
compared with other antiviral drugs for the treatment of COVID‐19 patients. We aimed to …

Background In randomized controlled trials, Nirmatrelvir/ritonavir (NMV/r) and Molnupiravir
(MPV) reduced the risk of severe/fatal COVID-19 disease. Real-world data are limited …

The effect of nirmatrelvir plus ritonavir (NMV‐r) on post‐acute COVID‐19 sequelae beyond 3
months of SARS‐CoV‐2 infection remains unknown. This retrospective cohort study utilized …

Background: Nirmatrelvir/ritonavir (NMV/r) is an oral antiviral drug used to treat mild-to-
moderate coronavirus disease 2019 (COVID-19) in patients aged 12 years or older at high …

The aim of this study was to investigate the clinical efficacy of a combination of nirmatrelvir
and ritonavir (NMV‐r) for treating COVID‐19 in patients with diabetes mellitus (DM). This …